VSBS targets herpes viruses
That's Venus Beauty Supply, Inc, now FermaVir Research.
***************************************
Venus Beauty Supply, Inc. Announces Acquisition of FermaVir Research, Inc, Closing of Placement, and Name Change
Tuesday August 23, 7:30 am ET
NEW YORK--(BUSINESS WIRE)--Aug. 23, 2005--Venus Beauty Supply, Inc. (OTCBB:VSBS - News) today announced that its 35.28 stock split and name change to "FermaVir Pharmaceuticals, Inc." became effective August 22, 2005, as anticipated. Beginning with the opening of the OTCBB on August 23, 2005, the company's common stock will be quoted under the symbol "FMVR."
ADVERTISEMENT
FermaVir is a development stage biotechnology company that has licensed patents for a series of compounds for the treatment of viral diseases including compounds for the treatment of varicella zoster virus ("VZV"), the causative agent for shingles and chickenpox and human cytomegalovirus ("CMV"), a member of the herpes virus group which includes the viruses that cause chicken pox, mononucleosis, herpes labialis (cold sores) and genitalis (genital herpes). FermaVir is currently performing preclinical studies on its compounds in order to select a clinical candidate for development for the treatment of shingles. In addition, FermaVir intends to identify from its proprietary anti-viral compounds, a clinical candidate for the treatment of CMV infections in transplant patients. FermaVir is also currently seeking other opportunities and technologies for in-licensing from academic, research institutions and commercial sources which would complement and enhance its business.
More Information regarding the company and its FermaVir Research, Inc. subsidiary can be found in the company's Form 8-K Report filed with the Securities and Exchange Commission on August 22, 2005.
Contact:
FermaVir Pharmaceuticals, Inc.
Geoffrey W. Henson, 212-375-2630
